Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed — regulatory update affecting Pharmaceutical Manufacturing (FDA/DEA).
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 11, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers) should confirm how it applies to their specific situation before acting. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Generic Clearance for Qualitative Data To Support Social and Behavioral Research for Food, Dietary Supplements, Cosmetics, and Animal Food and Feed
Who it affects
Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers)
What you must do
Note this update; no immediate action appears required, but monitor for follow-on rules.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Pharmalittle: We're reading about an FDA rejection, the Big Beautiful Bill's cost, and much more - STAT
- Bulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc.
- Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Customer/Partner Customer Service Satisfaction Surveys
- Evotec Opens cGMP Manufacturing Facility in Redmond, WA - Contract Pharma
- Asahi Kasei Enters Global License Agreement with Alchemedicine - Contract Pharma